The Recall Desk
SevereFDA (Drugs)·D-66318-001·Announced 2013-11-13

Amgen Recalls Prolia Injection Due to Visible Cellulose Fibers

Amgen is recalling 4,163 Prolia (denosumab) prefilled syringes because visible cellulose fibers were found during routine quality checks.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The FDA classified this recall as Class II, which corresponds to a 'Severe' severity score under the rubric, as it may cause temporary or medically reversible adverse health consequences.

Plain-English summary

Amgen, Inc. is recalling 4,163 prefilled syringes of Prolia (denosumab) Injection, 60 mg/mL. The recall affects Lot #1037592, which has an expiration date of 07/15. The product is distributed nationwide, in Puerto Rico, Canada, Mexico, and through clinical distribution in Europe.

The recall was initiated because visible cellulose fibers were observed in a small number of prefilled syringes during a routine quality examination. The FDA has classified this recall as Class II, indicating a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.

Healthcare providers and patients should stop using the affected syringes and contact Amgen or their local FDA office for further instructions. Consumers should check their medication packaging for the specific lot number and expiration date listed above to determine if they are affected.

The recalled product

Product
PROLIA (DENOSUMAB)
Brand
PROLIA
Manufacturer
Amgen, Inc.
Affected units
4,163

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot #: 1037592
  • Exp 07/15

UPCs (1)

  • 355513710015

Distribution

Distributed nationwide across the United States.

The notice also names 1 state specifically: